#oncology #BeOneMedicines #UKinnovationpassport #HCCtherapy #hepatocellularcarcinoma #livercancer #investigationalantibody #InnovationPassport #bispecificantibody #BGBB2033 #InnovativeLicensingandAccessPathway #MHRA #patientaccess #ILAP #investigationalmedicine #ILAPPartners
zurl.co/aWAU6
zurl.co/aWAU6
BeOne Medicines secures UK innovation passport for HCC therapy - PharmaTimes
Designation supports accelerated access for investigational antibody
pharmatimes.com
August 10, 2026 at 9:01 AM